A FoB program or the M118 program would not have a need for any immediate funding.
I strongly disagree with respect to the FoB programs. A decision to proceed in earnest with even one FoB* program requires a serious up-front commitment of capital to ensure that the program can be brought to fruition on a reasonable schedule.
I’ve already posted why I don’t think the money is for M118, so I won’t bother to repeat that here.
*Presumably for a monoclonal antibody.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”